![Hans Clevers](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hans Clevers
Direktor/Vorstandsmitglied bei
F. Hoffmann-La Roche Ltd.
Profil
Hans Clevers is the founder of Surrozen Operating, Inc. (2015) and Xilis, Inc. (2019).
Current jobs include Director at F.
Hoffmann-La Roche Ltd. (2019) and Professor-Molecular Genetics at the University of Utrecht (2002).
Former jobs include Director at Genentech, Inc., Director at the American Association for Cancer Research (2012-2015), Director-Royal Netherlands Academy at Hubrecht Institute (2002-2012), Research Director at Princess Maxima Centre For Pediatric Oncology (2015-2019), Venture Partner at EQT Life Sciences Group BV (2001-2022), President at The Royal Netherlands Academy of Arts & Sciences (2012-2015), President at The International Society for Stem Cell Research (2017-2018), President at International Society of Differentiation, Inc. (2006-2008), Chief Scientific Officer at Hubrecht Organoid Technology Foundation (2014-2020), and Head-Pharma Research & Early Development at Roche Holding AG (2022-2025).
Education includes graduate (1982) and doctorate (1985) degrees from the University of Utrecht.
Aktive Positionen von Hans Clevers
| Unternehmen | Position | Beginn |
|---|---|---|
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Direktor/Vorstandsmitglied | 05.03.2019 |
University of Utrecht
 University of Utrecht Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.1989 |
Ehemalige bekannte Positionen von Hans Clevers
| Unternehmen | Position | Ende |
|---|---|---|
| ROCHE HOLDING AG | Direktor/Vorstandsmitglied | 18.03.2022 |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance EQT Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, medical devices, diagnostics and healthtech sectors. It provides financing for early and later stage capital requirements with an investment size of EUR 10 – 60 million. | Mitglied des Investmentausschusses | 28.02.2022 |
Hubrecht Organoid Technology Foundation | Corporate Officer/Principal | 01.01.2020 |
Princess Maxima Centre For Pediatric Oncology | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
The International Society for Stem Cell Research
 The International Society for Stem Cell Research The International Society for Stem Cell Research (ISSCR) is a nonprofit organization dedicated to advancing stem cell science and its applications to human health. The non-profit company is based in Deerfield, IL. It represents nearly 5,000 members from over 80 countries, including scientists, educators, ethicists, clinicians, and business leaders. ISSCR promotes rigorous and ethical research through the development of international guidelines and quality standards, and provides resources such as the open-access journal Stem Cell Reports, standards documents for human stem cell use, and educational programs including annual meetings, symposia, webinars, and on-demand scientific content. The society supports workforce development by engaging early career scientists and trainees, fosters collaboration through a directory of stem cell societies and institutes, and conducts advocacy and policy efforts to provide scientific input to regulatory agencies and combat unproven stem cell therapies. ISSCR emphasizes equity, diversity, and inclusion, and offers resources for researchers, clinicians, educators, patients, and policymakers. The organization facilitates access to funding opportunities, supports continuing education, and promotes public and patient education. Membership benefits include networking, reduced fees for meetings and publishing, and access to scientific content. | Präsident | 01.01.2018 |
Ausbildung von Hans Clevers
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
79
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Roche Holding AG
 Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics | Health Technology |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
LSP Management Group BV
LSP Management Group BV Investment ManagersFinance EQT Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, medical devices, diagnostics and healthtech sectors. It provides financing for early and later stage capital requirements with an investment size of EUR 10 – 60 million. | Finance |
University of Utrecht
University of Utrecht Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American Association for Cancer Research
 American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services Engages in research, education, communication and collaboration to prevent and cure cancer | Commercial Services |
The Royal Netherlands Academy of Arts & Sciences
 The Royal Netherlands Academy of Arts & Sciences Miscellaneous Commercial ServicesCommercial Services Provides research services in the field on science and art | Commercial Services |
The International Society for Stem Cell Research
The International Society for Stem Cell Research The International Society for Stem Cell Research (ISSCR) is a nonprofit organization dedicated to advancing stem cell science and its applications to human health. The non-profit company is based in Deerfield, IL. It represents nearly 5,000 members from over 80 countries, including scientists, educators, ethicists, clinicians, and business leaders. ISSCR promotes rigorous and ethical research through the development of international guidelines and quality standards, and provides resources such as the open-access journal Stem Cell Reports, standards documents for human stem cell use, and educational programs including annual meetings, symposia, webinars, and on-demand scientific content. The society supports workforce development by engaging early career scientists and trainees, fosters collaboration through a directory of stem cell societies and institutes, and conducts advocacy and policy efforts to provide scientific input to regulatory agencies and combat unproven stem cell therapies. ISSCR emphasizes equity, diversity, and inclusion, and offers resources for researchers, clinicians, educators, patients, and policymakers. The organization facilitates access to funding opportunities, supports continuing education, and promotes public and patient education. Membership benefits include networking, reduced fees for meetings and publishing, and access to scientific content. | |
Hubrecht Institute
 Hubrecht Institute BiotechnologyHealth Technology Develops biology and stem cells | Health Technology |
International Society of Differentiation, Inc.
 International Society of Differentiation, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research, development and communication in fields of cell and molecular biology & oncology | Commercial Services |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Discovers and develops novel regenerative medicines | Health Technology |
Princess Maxima Centre For Pediatric Oncology | |
Hubrecht Organoid Technology Foundation | |
Xilis, Inc.
 Xilis, Inc. Medical SpecialtiesHealth Technology Develops droplet-based microfluidics technology devices for precision cancer diagnostics and drug development | Health Technology |
Wählen Sie MarketScreener 
